Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer

Lung Cancer

Volumn 40, Issue 1, 2003, Pages 91-97

  Socinski, Mark A ^a   Neubauer, Marcus A ^b   Olivares, Jairo ^b   Ketchel, Steven ^b   Tynan, Maureen ^b   Moore, Martha ^b   Lee, Ji Hyun ^b   Davis, Kim ^b   Schell, Michael ^b   Garfield, David ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

Carboplatin; Chemotherapy; Clinical trial; Ifosfamide; Paclitaxel; Small cell lung cancer

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; IFOSFAMIDE; MESNA; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEATH; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0037379171     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00527-5     Document Type: Article

References (29)

1. Gillenwater H.H., Socinski M.A. Extensive stage small cell lung cancer. Detterbeck F.C., Rivera M.P., Socinski M.A., Rosenman J.G. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. 2001;WB Saunders, Philadelphia, PA.
2. Noda K., Nishiwaki A., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell-lung cancer. N. Engl. J. Med. 346:(2):2002;85-91.
3. Niell H.B., Herndon J.E., Miller A.A., et al. Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF inpatients with extensive stage small cell lung cancer (ED-SCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;293a. abstract 1169.
4. Mavroudis D., Papadakis E., Veslemes M., et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann. Oncol. 12:(4):2001;463-470.
5. Schiller J., Adak S., Cella D., et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J. Clini. Oncol. 19:(8):2001;2114-2122.
6. Hanna N.H., Sandier A.B., Loehrer P.J. Sr., et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann. Oncol. 13:(1):2002;95-102.
7. Pujol J.L., Daures J.P., Riviere A., et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxurubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J. Nat. Cancer Inst. 93:(4):2001;300-308.
8. Thatcher N., Girling D.J., Hopwood P., et al. Improving survival without reducing quality of life in small-call lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J. Clin. Oncol. 18:(2):2000;395-404.
9. Groen H.J.M., Fokkema E., Biesma B. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, cloxorubicin, and etoposide: a non-cross-resistant schedule. J. Clin. Oncol. 17:1999;927-932.
10. Ettinger D.S. The place of ifosfamide in chemotherapy of small cell lung cancer: The Eastern Cooperative Oncology Group experience and a selected literature update. Semin. Oncol. 22:(1, Suppl 2):1995;23-27.
11. Loehrer P.J., Ansari R., Conin R. Cisplatin plus etoposide with and without ifosfamide in extensive small cell lung cancer. J. Clin. Oncol. 13:1995;2594-2599.
12. Kosmas C., Tsavaris N.B., Malamos N.A. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J. Clin. Oncol. 19:2001;119-126.
13. van Putten J.W., Kerbush T., Smit E.F., et al. Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. Ann. Oncol. 12:(6):2001;787-792.
14. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1989;1748-1756.
15. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
16. Cella D. Measurement system. 1997;Evanston Northwestern Healthcare and Northwestern University, Evanston, IL.
17. Cella D., Bonomi A.E., Lloyd S.R., et al. Reliability and validity of the of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer. 12:1995;199-200.
18. Hollen P.J., Gralla R., Kris M.G., et al. Normative data and trends in quality of life from the lung cancer symptom scale (LCSS) supportive care. Cancer. 1999;140-148.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials. 10:1989;1-10.
20. Skarlos D.V., Samantas E., Kosmidis P. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Group study. Ann. Oncol. 5:1994;601-607.
21. Clark J.A., Rosenman J.G., Detterbeck F.C. Radiotherapy alone for stage IIIA, B non-small cell lung cancer. Detterbeck F.C., Rivera M.P., Socinski M.A., Rosenman J.G. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. 2001;WB Saunders, Philadelphia, PA.
22. Parker R.J., Dabholkar M.D., Lee K.B. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J. Natl. Cancer Inst. 15:1993;83-88.
23. Bunnell C.A., Thompson L., Buswell L. Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer. 82:1998;561-566.
24. Thomas P., Castelnau O., Paillotin D., et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer. J. Clin. Oncol. 19:(5):2001;1320-1325.
25. Zaniboni A., Meriggi F., Rizzi A. Paclitaxel, ifosfamide, and carboplatin for the treatment of stage IIIB and IV non-small cell lung cancer. Semin. Oncol. 24:(Suppl 12):1997;70-72.
26. Bajorin D.F., McCaffrey J.A., Hilton S. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J. Clin. Oncol. 16:1998;2722-2727.
27. Schilder L.E., Albain K.S., Hantel A., et al. Phase I trial of taxol, ifosfamide, cisplatin (TIC) in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 13:1994;404. abstract 1378.
28. Greco F.A., Hainsworth J.D. One hour paclitaxel infusion schedule: a phase I/II comparative trial. Semin. Oncol. 22:1995;118-123.
29. Cella D., Eton D., Fairclough D., et al. What is a clinically meaningful change on the functional assessment of cancer therapy (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study E5592. J. Clin. Oncol. 55:2002;285-295.